Alkermes Controlled Therapeutics, Inc., University of Massachusetts
대리인 / 주소
Hamilton, Brook, Smith & Reynolds, P.C.
인용정보
피인용 횟수 :
14인용 특허 :
37
초록▼
The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contact
The invention relates to an improved method for administering live cells to a patient and compositions useful in the method. The composition comprises live cells and biocompatible, biodegradable polymer microparticles. The cells and microparticles of the cell/microparticle composition can be contacted immediately prior to administration, or can be contacted in culture for a specified period of time prior to administration. In the method of the invention, an effective amount of the cell/microparticle composition is administered to a patient in need thereof by injection to a treatment site of the patient to provide a therapeutic effect in the patient. The therapeutic effect can be, for example, the formation of new tissue at the treatment site, or the production and secretion of a biologically active secretory molecule at the treatment site. The composition comprising lives cells and biocompatible, biodegradable polymer microparticles can further comprise a biologically active agent. In a preferred embodiment, the biologically active agent is incorporated into the microparticle. The biologically active agent can be, for example, factors which modulate cell growth.
대표청구항▼
1. A method of generating cartilage tissue in a patient in need thereof consisting essentially of administering by injection to a treatment site of the patient without open surgery to expose the treatment site an effective amount of a composition consisting essentially of live chondrocytes and bioco
1. A method of generating cartilage tissue in a patient in need thereof consisting essentially of administering by injection to a treatment site of the patient without open surgery to expose the treatment site an effective amount of a composition consisting essentially of live chondrocytes and biocompatible, biodegradable polymer microparticles wherein, the microparticles are injected in an amount sufficient to provide a surface for the chondrocytes to grow and generate said tissue. 2. The method of claim 1 wherein the the biocompatible, biodegradable polymer of the microparticle is selected from poly(lactides), poly(glycolides), poly(lactide-co-glycolides), poly(lactic acid)s, poly(glycolic acid)s, polycarbonates, polyesteramides, polyanydrides, poly(amino acids), polyorthoesters, poly(dioxanone)s, poly(alkylene alkylate)s, copolymers of polyethylene glycol and polyorthoester, polyurethanes, blends thereof, and copolymers thereof. 3. The method of claim 2 wherein the biocompatible, biodegradable polymer is a poly(lactide-co-glycolide). 4. The method of claim 1 wherein the composition further consisting essentially of a pharmaceutically acceptable carrier. 5. The method of claim 1 wherein the composition further consisting essentially of a biologically active agent. 6. The method of claim 5 wherein the biologically active agent has cartilage regeneration inductive properties. 7. The method of claim 5 wherein the biologically active agent is a growth factor or differentiating factor. 8. The method of claim 7 wherein the growth factor is selected from basic fibroblast growth factor (bFGF), platelet-derived growth factors (PDGF), transforming growth factors (TGF-α, TGF-β), cementum growth factors, epidermal growth factor (EGF), hepatocyte growth factor, heparin binding factor, insulin-like growth factors I or II (IGF-I, IGF-II), erythropoietin, and nerve growth factor (NGF). 9. The method of claim 7 wherein the differentiating factor is a morphogenic protein. 10. The method of claim 9 wherein the morphogenic protein is selected from OP-1, OP-2, OP-3, BMP2, BMP3, BMP4, BMP5, BMP6 and active fragments and derivatives thereof. 11. The method of claim 1 wherein the concentration of cells in the composition is from about 0.5×106cells/mL to about 50×106cells/mL. 12. The method of claim 1 wherein the treatment site is the articular space of a joint of the patient.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (37)
Sittinger Michael,DEX ; Schultz Olaf,DEX ; Burmester Gerd R.,DEX ; Haupl Thomas E. M.,DEX, Artificial tissues, methods for the production and the use thereof.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Johnson OluFunmi Lily (Cambridge MA) Ganmukhi Medha M. (Wexford PA) Bernstein Howard (Cambridge MA) Auer Henry (Belmont MA) Khan M. Amin (Dowington PA), Composition for sustained release of human growth hormone.
Zale Stephen E. (Hopkington MA) Burke Paul A. (Medford MA) Bernstein Howard (Cambridge MA) Brickner Avram (Brookline MA), Composition for sustained release of non-aggregated erythropoietin.
Laurance Megan E. (Portland OR) Knaack David (Chepachet RI) Fiore Deborah M. (Swansea MA) Hegre Orion D. (Chepuchet RI), Glucose responsive insulin secreting b
상세보기
Piwnica-Worms Helen, Human Myt1 protein and chimeric proteins derived therefrom.
Polson Alan M. ; Swanbom Deryl D. ; Dunn Richard L. ; Cox Charles P. ; Norton Richard L. ; Lowe Bryan K. ; Peterson Kenneth S., Method and composition for treating a bone tissue defect.
Schinstine Malcolm ; Shoichet Molly S.,CAX ; Gentile Frank T. ; Hammang Joseph P. ; Holland Laura M. ; Cain Brian M. ; Doherty Edward J. ; Winn Shelley R. ; Aebischer Patrick,CHX, Method for controlling proliferation and differentiation of cells encapsulated within bioartificial organs.
Holland Laura M. (Providence RI) Hammang Joseph P. (Barrington RI) Rudnick Seth A. (Barrington RI) Lysaght Michael J. (E. Greenwich RI) Dionne Keith E. (Rehoboth MA), Method for implanting encapsulated cells in a host.
Schinstine Malcolm ; Shoichet Molly S.,CAX ; Gentile Frank T. ; Hammang Joseph P. ; Holland Laura M. ; Cain Brian M. ; Doherty Edward J. ; Winn Shelley R. ; Aebischer Patrick,CHX, Methods and compositions of growth control for cells encapsulated within bioartificial organs.
Bernstein Howard (Cambridge MA) Zhang Yan (Cambridge MA) Khan M. Amin (Downingtown PA) Tracy Mark A. (Arlington MA), Modulated release from biocompatible polymers.
Jones William K. ; Tucker Ronald F. ; Rueger David C. ; Oppermann Hermann ; Ozkaynak Engin ; Kuberasampath Thangavel, Morphogenic protein compositions of matter.
Vacanti Joseph P. (Winchester MA) Vacanti Charles A. (Lexington MA) Langer Robert S. (Newton MA), Neomorphogenesis of cartilage in vivo from cell culture.
Rueger David C. (Hopkinton MA) Kuberasampath Thangavel (Medway MA) Oppermann Hermann (Medway MA) Ozkaynak Engin (Milford MA), Prosthetic devices having enhanced osteogenic properties.
Gombotz Wayne R. (Lexington MA) Healy Michael S. (E. Bridgewater MA) Brown Larry R. (Newton MA), Very low temperature casting of controlled release microspheres.
Latham, John A.; Ojala, Ethan W.; Smith, Jeffrey T. L.; Dutzar, Benjamin H.; Garcia-Martinez, Leon F., Anti-NGF antibodies that selectively inhibit the association of NGF with TRKA without affecting the association of NGF with P75.
Latham, John A.; Ojala, Ethan W.; Smith, Jeffrey T. L.; Dutzar, Benjamin H.; Garcia-Martinez, Leon F., Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with P75.
Latham, John; Ojala, Ethan W.; Smith, Jeffrey T. L.; Dutzar, Benjamin H.; Garcia-Martinez, Leon F., Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75.
Garcia-Martinez, Leon F.; Dutzar, Benjamin H.; Ojala, Ethan W.; Smith, Jeffrey T. L.; Latham, John A., Methods of preventing inflammation and treating pain using anti-NGF compositions.
Garcia-Martinez, Leon F.; Dutzar, Benjamin H.; Ojala, Ethan W.; Smith, Jeffrey T. L.; Latham, John A., Methods of preventing inflammation and treating pain using anti-NGF compositions.
Garcia-Martinez, Leon F.; Latham, John A.; Ojala, Ethan W.; Akatsuka, Corinne C.; Fan, Pei; Smith, Jeffrey T. L.; Dutzar, Benjamin H., Methods of preventing or treating pain using anti-NGF antibodies.
Garcia-Martinez, Leon F.; Latham, John; Ojala, Ethan W.; Akatsuka, Corinne C.; Fan, Pei; Smith, Jeffrey T. L.; Dutzar, Benjamin H., Methods of preventing or treating pain using anti-NGF antibodies.
Latham, John A.; Ojala, Ethan W.; Smith, Jeffrey T. L.; Dutzar, Benjamin H.; Garcia-Martinez, Leon F., Methods of preventing or treating pain using anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.